Allopurinol Protection in Patients Undergoing Coronary Artery Bypass Graft Surgery

REFERENCES

• Marx JL. The 1988 Nobel Prize for physiology or medicine. Science.1988;242:516–517.
   PubMedGoogle Scholar
• Brunton LL, Lazo JS, Parker KL. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th ed. New York: McGraw-Hill, 2006.
   Google Scholar
• Crowell JW, Jones CE, Smith EE. Effect of allopurinol on hemorrhagic shock. Am J Physiol. 1969;216:744–748.
   PubMedGoogle Scholar
• Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58:87–114.
   PubMed Web of Science ®Google Scholar
• Parks DA, Bulkley GB, Granger DN, Ischemic injury in the cat small intestine: role of superoxide radicals. Gastroenterology 1982;82:9–15.
   PubMed Web of Science ®Google Scholar
• McCord JM, Roy RS, Schaffer SW. Free radicals and myocardial ischemia: the role of xanthine oxidase. Adv Myocardiol. 1985;5:183–189.
   PubMedGoogle Scholar
• McCord JM, Fridovitch I. The utility of superoxide dismutase in studying free radical reactions. I. Radicals generated by the interaction of sulfite, dimethyl sulfoxide, and oxygen. J Biol Chem. 1969;244:6056–6063.
   PubMed Web of Science ®Google Scholar
• Lasley RD, Ely SW, Berne RM, Allopurinol enhanced adenine nucleotide repletion after myocardial ischemia in the isolated rat heart. J Clin Invest. 1988;81:16–20.
   PubMedGoogle Scholar
• Lindsay WG, Toledo-Pereyra LH, Foker JE, Metabolic myocardial protection with allopurinol during cardiopulmonary bypass and aortic cross-clamping. Surg Forum. 1975;26: 259–260.
   PubMedGoogle Scholar
• Kang SM, Lim S, Song H, Allopurinol modulates reactive oxygen species generation and Ca2+ overload in ischemia-reperfused heart and hypoxia-reoxygenated cardiomyocytes. Eur J Pharmacol. 2006;535:212–219.
   PubMed Web of Science ®Google Scholar
• DeWall RA, Vasko KA, Stanley EL, Responses of the ischemic myocardium to allopurinol. Am Heart J. 1971;82: 362–370.
   PubMedGoogle Scholar
• Coghlan JG, Flitter WD, Clutton SM, Allopurinol pretreatment improves postoperative recovery and reduces lipid peroxidation in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg. 1994;107:248–256.
   PubMed Web of Science ®Google Scholar
• Gimpel JA, Lahpor JR, Van Der Molen AJ, Reduction of reperfusion injury of human myocardium by allopurinol: a clinical study. Free Radic Biol Med. 1995;19:251–255.
   PubMedGoogle Scholar
• Johnson WD, Kayser KL, Brenowitz JB, A randomized controlled trial of allopurinol in coronary bypass surgery. Am Heart J. 1991;121:20–24.
   PubMed Web of Science ®Google Scholar
• Rashid MA, William-Olsson G. Influence of allopurinol on cardiac complications in open heart operations. Ann Thorac Surg. 1991;52:127–130.
   PubMed Web of Science ®Google Scholar
• Castelli P, Condemi AM, Brambillasca C, Improvement of cardiac function by allopurinol in patients undergoing cardiac surgery. J Cardiovasc Pharmacol. 1995;25:119–125.
   PubMedGoogle Scholar
• Coetzee A, Roussouw G, Macgregor L. Failure of allopurinol to improve left ventricular stroke work after cardiopulmonary bypass surgery. J Cardiothorac Vasc Anesth. 1996;10:627– 633.
   PubMedGoogle Scholar
• Tarkka MR, Kaukinen S, Holm P, Allopurinol does not increase free radical scavenging capacity during reperfusion in coronary artery bypass graft patients. Scand Cardiovasc J. 2000;34:409–414.
   PubMedGoogle Scholar
• Zoran P, Juraj F, Ivana D, Effects of allopurinol on oxygen stress status during open heart surgery. Int J Cardiol. 1994;44:123–129.
   PubMedGoogle Scholar
• The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 9th ed. Boston, MA: Little, Brown and Co; 1994:253–256.
   Google Scholar
• Campeau L. The Canadian Cardiovascular Society of angina pectoris revisited 30 years later. Can J Cardiol. 2002;18:371– 379.
   PubMedGoogle Scholar
• Craddock D, Iyer VS, Russell WJ. Factors influencing mortality and myocardial infarction after coronary artery bypass grafting. Curr Opin Cardiol. 1994;9:664–669.
   PubMedGoogle Scholar
• Royster RL, Butterworth JF, Prough DS, Preoperative and intraoperative predictors of inotropic support and long-term outcome in patients having coronary artery bypass grafting. Anesth Analg. 1991;72:729–736.
   PubMed Web of Science ®Google Scholar
• Slogoff S, Keats AS, Cooley DA, Addition of papaverine to cardioplegia does not reduce myocardial necrosis. Ann Thorac Surg. 1986;42:60–64.
   PubMedGoogle Scholar
• Iyer VS, Russell WJ, Leppard P, Mortality and myocardial infarction after coronary artery surgery: a review of 12,003 patients. Med J Aust. 1993;159:166–170.
   PubMedGoogle Scholar
• Gersh BJ, Califf RM, Loop RD, Coronary bypass surgery in chronic stable angina. Circulation 1989;79: I-46–I-59.
   PubMedGoogle Scholar
• Allen RE, Claxon AWD, Blake DR, Inhibition of xanthine oxidase by allopurinol: its lack of effect on models of inflammation. Ann Rheum Dis. 1990;49:422–423.
   PubMedGoogle Scholar
• Toledo-Pereyra LH, Simmons RL, Olson LC, Clinical effect of allopurinol on preserved kidneys: a randomized double-blind study. Ann Surg. 1977;185:128–131.
   PubMedGoogle Scholar
• Toledo-Pereyra LH, Najarian JS. Total recovery of ischemic kidneys treated with allopurinol before transplantation. Surg Forum. 1973;24:302–304.
   PubMedGoogle Scholar
• Toledo-Pereyra LH. Restoration of function after ischemic injury on kidneys treated with allopurinol. Thesis (PhD), University of Minnesota, 1976.
   Google Scholar
• Mueller DK, Stout M, Blakeman BM. Morbidity and mortality of intra-aortic balloon pumps placed through the aortic arch. Chest 1998;114:85–88.
   PubMedGoogle Scholar
• Herlitz J, Brandrup-Wognsen G, Evander MH, Quality of life 15 years after coronary artery bypass grafting. Coron Artery Dis. 2009;20(6):363–369.
   PubMedGoogle Scholar